Alector, Inc.
Moat Score — Alector, Inc.
Total Moat Score
7 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Alector holds patents and deep scientific know-how around its immuno-neurology antibody platform and microglial biology, representing genuine intellectual and technical differentiation, though still unproven at the pivotal clinical stage. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a clinical-stage biotech, Alector has no manufacturing or operational cost advantage; its economics depend on partnership funding rather than scale efficiencies. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | With no approved products, Alector has no current pricing power, and any future neurodegenerative disease therapy pricing would be heavily influenced by payer negotiations and comparison to approved competitors like Leqembi and Kisunla. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Biopharmaceutical drug development and therapeutics exhibit no network effects. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | With no marketed products, there are no existing patients or prescribers to create switching costs; this would only become relevant following a successful launch. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The neurodegenerative disease therapeutic market is large and well-funded, attracting major pharmaceutical competitors pursuing multiple mechanisms, so efficient scale provides little protection to Alector's specific immuno-neurology approach. |